• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • major adverse cardiovascular events
Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis
Posted inCardiology Diabetes & Endocrinology news

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

Posted by By MedXY 10/19/2025
This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes status.
Read More
Interleukin-17 Inhibitors and Cardiovascular Risk: Evaluating Early Major Adverse Cardiovascular Events
Posted inAllergy & Immunology Cardiology Clinical Updates Dermatology news Specialties

Interleukin-17 Inhibitors and Cardiovascular Risk: Evaluating Early Major Adverse Cardiovascular Events

Posted by By MedXY 09/03/2025
A national database study finds no significant increase in early major adverse cardiovascular events (MACEs) after starting IL-17 inhibitors in psoriasis and related diseases, although a modest risk cannot be excluded.
Read More
High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI
Posted inCardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

Posted by By MedXY 08/16/2025
This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.
Read More
  • Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters
  • Long-term Outcomes in Congenital TTP: Registry Data Show Prophylactic Plasma Reduces Clinical Events but Symptoms and Product Burden Persist
  • DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
  • DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
  • Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial depression diabetes diet epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial screening sexual health sleep treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in